NDAINHALATIONGAS
Approved
Nov 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
NITROUS OXIDE, USP (nitrous oxide) by Medica Corp. Approved for anesthesia, sedation, pain and 2 more indications. First approved in 2014.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nitrous oxide (N2O) is an inhalational gas anesthetic and sedative agent used for pain relief, anxiolysis, and conscious sedation across dental, surgical, and emergency medicine settings. It is administered via inhalation as a colorless, odorless gas that produces rapid onset anesthesia and sedation. The precise mechanism remains incompletely characterized but involves CNS depression through interaction with multiple neurotransmitter systems.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable commercial operations and ongoing market defense activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (5)
Worked on NITROUS OXIDE, USP at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.